Study Stopped
Principal Investigator left the institution before subjects were enrolled
Airway Pressure Release Ventilation as a Preventative Strategy
1 other identifier
interventional
N/A
0 countries
N/A
Brief Summary
The early initiation of Airway Pressure Release Ventilation in multi-system trauma patients decreases the incidence and severity of acute lung injury and Acute Respiratory Distress Syndrome and allows faster recovery of lung function.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Dec 2008
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2008
CompletedFirst Submitted
Initial submission to the registry
December 22, 2008
CompletedFirst Posted
Study publicly available on registry
December 23, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2011
CompletedAugust 25, 2009
August 1, 2009
3 years
December 22, 2008
August 24, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The primary endpoint will be the number of ventilator-free days.
from randomization to study termination
Secondary Outcomes (2)
effects of ventilator mode on ventilation
duration of ventilatory assistance
duration of ICU stay
time in ICU
Study Arms (2)
1
ACTIVE COMPARATORAirway Pressure Release Ventilation Arm
2
ACTIVE COMPARATORARDSnet protocol
Interventions
Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
Eligibility Criteria
You may qualify if:
- Trauma patients age 16 or older
- Trauma patients requiring ventilatory support within 48 hours of injury
- Those with anticipated ventilatory support ≥ 24 hours
- Subject or authorized representative (AR) has signed an informed consent form (ICF)
- Subjects age 16 or 17 who have signed an assent document and/or AR has signed an ICF
You may not qualify if:
- Significant chronic lung disease defined as lung pathology requiring home O2 use
- Chronic heart disease defined as NYHC III or higher
- Persistent bronchopulmonary air leak
- Contraindications to permissive hypercapnia (ex. Intracerebral bleeding, brain tumor, fulminant hepatic failure, and hemodynamic instability)
- Pulmonary artery occlusion pressures ≥ 18 mmHg
- Severe neurologic injury that may prevent the patient from having a reasonable opportunity for weaning as determined by the clinical study team
- Immuno-compromised patients secondary to drugs or disease
- Neuromuscular disease that impairs ability to ventilate spontaneously (ex. Spinal injury at or above C5, ALS, Guillain-Barre syndrome, Myasthenia Gravis)
- History of pneumonectomy
- Pregnancy
- Burns with TBSA ≥ 20%
- Acute MI as the cause of ALI/ARDS
- All other contraindications to APRV
- Patients who cannot be randomized within 12 hours of intubation
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jack Shannon, M.D.
Texas Tech University Health Sciences Center
- STUDY DIRECTOR
John Griswold, M.D.
Texas Tech University Health Sciences Center
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
December 22, 2008
First Posted
December 23, 2008
Study Start
December 1, 2008
Primary Completion
December 1, 2011
Study Completion
December 1, 2011
Last Updated
August 25, 2009
Record last verified: 2009-08